Congenital Pneumonia Medication

  • Author: Roger G Faix, MD; Chief Editor: Ted Rosenkrantz, MD   more...
 
Updated: Mar 29, 2011
 

Medication Summary

The frequency of bacterial infection as the primary cause or as a superimposed complication of pulmonary inflammation in general, and congenital pneumonia in particular, usually mandates antibiotic administration as the cornerstone of therapy.

Agents typically used initially include a combination of ampicillin and either gentamicin or cefotaxime. The selection of cefotaxime or gentamicin must be based on experience and considerations at each center and in each patient. Combination therapy provides reasonable antimicrobial efficacy against the pathogens that typically cause serious infection in the first days of life.

Other agents or combinations may be appropriate for initial empiric therapy if justified by the range of pathogens and susceptibilities encountered in a particular clinical setting.

Consultation of appropriate neonatal references, such as Neofax, is recommended when using antibiotics in these patients. Similarly, an appropriate reference should be used when using adjunctive therapy such as bronchodilators, mucolytics, nitric oxide, or epoprostenol.

Next

Antibiotics

Class Summary

The frequency of bacterial infection as the cause or a major complication of congenital pneumonia usually mandates antibiotics as a cornerstone of therapy.

View full drug information

Ampicillin

 

This parenteral agent offers antimicrobial efficacy against many pathogens encountered in infections that occur in the first few days of life, including, but not limited to, group B Streptococcus, many types of other streptococci, L monocytogenes, and some strains of E coli, enterococci, and nontypeable H influenzae.

View full drug information

Cefotaxime (Claforan)

 

Cefotaxime is a third-generation cephalosporin with gram-negative spectrum. Cefotaxime arrests bacterial cell wall synthesis, which in turn inhibits bacterial growth. When administered parenterally, this agent offers antimicrobial efficacy against many gram-negative pathogens that are commonly encountered in the first few days of life, including E coli, nontypeable H influenzae, Klebsiella species, and other enteric organisms. Cefotaxime crosses the blood-brain barrier into the CNS reasonably well and theoretically poses less risk of renal toxicity or ototoxicity than gentamicin and other aminoglycosides, which are the common alternatives. It is less likely than gentamicin to interfere with function of neuromuscular junction in infants born to mothers with myasthenia gravis.

However, compared with gentamicin, cefotaxime is more costly, is associated with much more rapid emergence of resistant organisms in a closed environment (eg, NICU), covers a slightly narrower range of gram-negative organisms, and has not been demonstrated to yield superior outcomes in a randomized controlled trial of neonatal patients.

View full drug information

Gentamicin

 

Gentamicin is an aminoglycoside antibiotic used for gram-negative coverage. Gentamicin is typically used in combination with agents against gram-positive organisms. When administered parenterally, this agent offers antimicrobial efficacy against many gram-negative pathogens commonly encountered in the first few days of life, including E coli, Klebsiella species, and other enteric organisms, as well as many strains of nontypeable H influenzae. It is also variably effective against some strains of certain gram-positive organisms, including S aureus, enterococci, and L monocytogenes.

Gentamicin crosses the blood-brain barrier into the CNS less well and theoretically poses greater risk of renal toxicity or ototoxicity than cefotaxime and other third-generation cephalosporins, which are the common alternatives. Compared with cefotaxime, gentamicin is less costly, is associated with much less rapid emergence of resistant organisms in a closed environment (eg, NICU), and covers a broader range of gram-negative organisms.

Gentamicin has been reported to offer additive or synergistic activity against enterococci when used with ampicillin.

View full drug information

Azithromycin

 

Empiric use of azithromycin or other macrolides for presumed Ureaplasma infection is not currently evidence based and should be reserved for infants who have that organism recovered from a normally sterile site or who are critically ill and do not have a more likely cause of infection. Azithromycin acts by binding to 50S ribosomal subunit of susceptible microorganisms and blocks dissociation of peptidyl tRNA from ribosomes, causing RNA-dependent protein synthesis to arrest. Nucleic acid synthesis is not affected. It concentrates in phagocytes and fibroblasts as demonstrated by in vitro incubation techniques. In vivo studies suggest that concentration in phagocytes may contribute to drug distribution to inflamed tissues.

View full drug information

Erythromycin (Ery-Tab, Erythrocin, EryPed, E.E.S.)

 

Erythromycin is a macrolide antibiotic with a large spectrum of activity. Erythromycin binds to the 50S ribosomal subunit of the bacteria, which inhibits protein synthesis.

Like azithromycin, the use of erythromycin for presumed Ureaplasma infection is not currently evidence based and should be reserved for infants who have that organism recovered from a normally sterile site or who are critically ill and do not have a more likely cause of infection.

Orally administered erythromycin has been associated with the development of infantile hypertrophic pyloric stenosis in infants younger than 1 month.

Previous
Next

Antivirals

Class Summary

Antiviral agents interfere with viral replication and weaken or abolish viral activity. An example of an antiviral agent is acyclovir (Zovirax).

View full drug information

Acyclovir (Zovirax)

 

Acyclovir treatment should be considered when a diagnosis of herpes simplex virus is suspected and when the infant is not responding to antibiotic therapy.

Previous
 
Contributor Information and Disclosures
Author

Roger G Faix, MD  Professor, Department of Pediatrics (Neonatology), University of Utah School of Medicine

Roger G Faix, MD is a member of the following medical societies: American Academy of Pediatrics, American Pediatric Society, American Society for Microbiology, National Perinatal Association, Society for Pediatric Research, and Utah Medical Association

Disclosure: Ikaria Consulting fee Consulting; Biosynexus Consulting fee Review panel membership

Specialty Editor Board

Steven M Donn, MD  Professor of Pediatrics, University of Michigan Medical School; Director, Division of Neonatal-Perinatal Medicine, Department of Pediatrics, CS Mott Children's Hospital, University of Michigan Health System

Steven M Donn, MD is a member of the following medical societies: American Pediatric Society

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Pharmacy Editor, eMedicine

Disclosure: Nothing to disclose.

Brian S Carter, MD, FAAP  Professor of Pediatrics (Neonatology), Vanderbilt University School of Medicine; Director, Neonatal Follow-up Program, Monroe Carell Jr Children's Hospital at Vanderbilt

Brian S Carter, MD, FAAP is a member of the following medical societies: Alpha Omega Alpha, American Academy of Hospice and Palliative Medicine, American Academy of Pediatrics, American Society for Bioethics and Humanities, American Society of Law, Medicine & Ethics, National Hospice and Palliative Care Organization, Society for Pediatric Research, and Southern Society for Pediatric Research

Disclosure: Nothing to disclose.

Chief Editor

Ted Rosenkrantz, MD  Professor, Departments of Pediatrics and Obstetrics/Gynecology, Division of Neonatal-Perinatal Medicine, University of Connecticut School of Medicine

Ted Rosenkrantz, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Pediatric Society, Connecticut State Medical Society, Eastern Society for Pediatric Research, and Society for Pediatric Research

Disclosure: Nothing to disclose.

References

  1. Barton L, Hodgman JE, Pavlova Z. Causes of death in the extremely low birth weight infant. Pediatrics. Feb 1999;103(2):446-51. [Medline].

  2. Duke T. Neonatal pneumonia in developing countries. Arch Dis Child Fetal Neonatal Ed. May 2005;90(3):F211-9. [Medline].

  3. Heron MP, Smith BL. Deaths: leading causes for 2003. Natl Vital Stat Rep. Mar 15 2007;55(10):1-92. [Medline].

  4. Nissen MD. Congenital and neonatal pneumonia. Paediatr Respir Rev. Sep 2007;8(3):195-203. [Medline].

  5. Feria-Kaiser C, Furuya ME, Vargas MH, Rodriguez A, Cantu MA,. Main diagnosis and cause of death in a neonatal intensive care unit: do clinicians and pathologists agree?. Acta Paediatr. 2002;91(4):453-8. [Medline].

  6. Barnett ED, Klein JO. Bacterial infections of the respiratory tract. In: Remington JS, Klein JO, eds. Infectious Diseases of the Fetus and Newborn Infant. 6th ed. Philadelphia, Pa: Elsevier Saunders Co; 2006:297-317.

  7. Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest. Jul 1997;112(1):235-43. [Medline].

  8. Stoll BJ, Hansen NI, Higgins RD, et al. Very low birth weight preterm infants with early onset neonatal sepsis: the predominance of gram-negative infections continues in the National Institute of Child Health and Human Development Neonatal Research Network, 2002-2003. Pediatr Infect Dis J. Jul 2005;24(7):635-9. [Medline].

  9. Kotecha S, Hodge R, Schaber JA, et al. Pulmonary Ureaplasma urealyticum is associated with the development of acute lung inflammation and chronic lung disease in preterm infants. Pediatr Res. Jan 2004;55(1):61-8. [Medline].

  10. Katz B, Patel P, Duffy L, Schelonka RL, Dimmitt RA, Waites KB. Characterization of ureaplasmas isolated from preterm infants with and without bronchopulmonary dysplasia. J Clin Microbiol. Sep 2005;43(9):4852-4. [Medline].

  11. Heggie AD, Bar-Shain D, Boxerbaum B, Fanaroff AA, O'Riordan MA, Robertson JA. Identification and quantification of ureaplasmas colonizing the respiratory tract and assessment of their role in the development of chronic lung disease in preterm infants. Pediatr Infect Dis J. Sep 2001;20(9):854-9. [Medline].

  12. Ballard HO, Bernard P, Whitehead V, et al. Determining the incidence of Ureaplasma spp. and its role in development of bronchopulmonary dysplasia. [Abstract 3858.111]. Pediatric Academic Societies Meeting 2009. Baltimore, MD. May 3, 2009. aps-spr.org. Available at www.abstracts2view.com/pas/view.php?nu=PAS09L1_3037. Accessed June 11, 2009.

  13. Haney PJ, Bohlman M, Sun CC. Radiographic findings in neonatal pneumonia. AJR Am J Roentgenol. Jul 1984;143(1):23-6. [Medline].

  14. Wiswell TE, Baumgart S, Gannon CM, Spitzer AR. No lumbar puncture in the evaluation for early neonatal sepsis: will meningitis be missed?. Pediatrics. Jun 1995;95(6):803-6. [Medline].

  15. Sherman MP, Goetzman BW, Ahlfors CE, Wennberg RP. Tracheal aspiration and its clinical correlates in the diagnosis of congenital pneumonia. Pediatrics. Feb 1980;65(2):258-63. [Medline].

  16. Giacoia GP, Neter E, Ogra P. Respiratory infections in infants on mechanical ventilation: the immune response as a diagnostic aid. J Pediatr. May 1981;98(5):691-5. [Medline].

  17. Chaaban H, Singh K, Huang J, Siryaporn E, Lim YP, Padbury JF. The role of inter-alpha inhibitor proteins in the diagnosis of neonatal sepsis. J Pediatr. Apr 2009;154(4):620-622.e1. [Medline].

  18. Gauvin F, Dassa C, Chaibou M, et al. Ventilator-associated pneumonia in intubated children: comparison of different diagnostic methods. Pediatr Crit Care Med. Oct 2003;4(4):437-43. [Medline].

  19. Gauvin F, Lacroix J, Guertin MC, et al. Reproducibility of blind protected bronchoalveolar lavage in mechanically ventilated children. Am J Respir Crit Care Med. Jun 15 2002;165(12):1618-23. [Medline].

  20. Labenne M, Poyart C, Rambaud C, et al. Blind protected specimen brush and bronchoalveolar lavage in ventilated children. Crit Care Med. Nov 1999;27(11):2537-43. [Medline].

  21. Klein JO. Diagnostic lung puncture in the pneumonias of infants and children. Pediatrics. Oct 1969;44(4):486-92. [Medline].

  22. Wigglesworth JS. Perinatal Pathology. 2nd ed. Philadelphia, Pa: WB Saunders Co; 1996:131-57, 184-7.

  23. Wynn JL, Neu J, Moldawer LL, Levy O. Potential of immunomodulatory agents for prevention and treatment of neonatal sepsis. J Perinatol. Feb 2009;29(2):79-88. [Medline].

  24. Ballard HO, Bernard P, Hayes D, et al. Use of azithromycin for the prevention of bronchopulmonary dysplasia: a randomized, double-blind, placebo controlled trial. [Abstract 4515.2]. Pediatric Academic Societies Meeting 2009. Baltimore, MD. May 4, 2009. aps-spr.org. Available at www.abstracts2view.com/pas/view.php?nu=PAS09L1_3053. Accessed June 11, 2009.

  25. Ballard HO, Bernard P, Whitehead V, et al. Use of azithromycin for the early treatment of Ureaplasma spp. in preterm infants: a randomized, double-blind, placebo controlled trial. [Abstract 4515.3]. Pediatric Academic Societies Meeting 2009. Baltimore, MD. May 4, 2009. aps-spr.org. Available at www.abstracts2view.com/pas/view.php?nu=PAS09L1_3037. Accessed June 11, 2009.

  26. Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. Empiric use of ampicillin and cefotaxime, compared with ampicillin and gentamicin, for neonates at risk for sepsis is associated with an increased risk of neonatal death. Pediatrics. Jan 2006;117(1):67-74. [Medline].

  27. de Man P, Verhoeven BA, Verbrugh HA, Vos MC, van den Anker JN. An antibiotic policy to prevent emergence of resistant bacilli. Lancet. Mar 18 2000;355(9208):973-8. [Medline].

  28. Braude AC, Hornstein A, Klein M, Vas S, Rebuck AS. Pulmonary disposition of tobramycin. Am Rev Respir Dis. May 1983;127(5):563-5. [Medline].

  29. Pennington JE. Penetration of antibiotics into respiratory secretions. Rev Infect Dis. Jan-Feb 1981;3(1):67-73. [Medline].

  30. Harding JE, Miles FK, Becroft DM, et al. Chest physiotherapy may be associated with brain damage in extremely premature infants. J Pediatr. Mar 1998;132(3 Pt 1):440-4. [Medline].

  31. van Kaam AH, Lachmann RA, Herting E, et al. Reducing atelectasis attenuates bacterial growth and translocation in experimental pneumonia. Am J Respir Crit Care Med. May 1 2004;169(9):1046-53. [Medline].

  32. Herting E, Gefeller O, Land M, et al. Surfactant treatment of neonates with respiratory failure and group B streptococcal infection. Members of the Collaborative European Multicenter Study Group. Pediatrics. Nov 2000;106(5):957-64; discussion 1135. [Medline].

  33. Herting E, Sun B, Jarstrand C, et al. Surfactant improves lung function and mitigates bacterial growth in immature ventilated rabbits with experimentally induced neonatal group B streptococcal pneumonia. Arch Dis Child Fetal Neonatal Ed. Jan 1997;76(1):F3-8. [Medline].

  34. [Guideline] Engle WA. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics. Feb 2008;121(2):419-32. [Medline]. [Full Text].

  35. NINOSG. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. The Neonatal Inhaled Nitric Oxide Study Group. N Engl J Med. Feb 27 1997;336(9):597-604. [Medline].

  36. ECMO. UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation. UK Collaborative ECMO Trail Group. Lancet. Jul 13 1996;348(9020):75-82. [Medline].

  37. IELSO. 1999 Summary Report of the Registry for International Extracorporeal Life Support Organization. 1999;1-10.

  38. AAP. Red Book. Available at http://aapredbook.aappublications.org/. Accessed November 18, 2010.

  39. Wiswell TE, Gannon CM, Jacob J, Goldsmith L, Szyld E, Weiss K, et al. Delivery room management of the apparently vigorous meconium-stained neonate: results of the multicenter, international collaborative trial. Pediatrics. Jan 2000;105(1 Pt 1):1-7. [Medline].

 
Previous
Next
 
Anteroposterior chest radiograph in an infant born at 28 weeks' gestation was performed following apnea and profound birth depression. Subtle reticulogranularity and prominent distal air bronchograms were consistent with respiratory distress syndrome, prompting exogenous surfactant and antimicrobial therapy. Initial smear of endotracheal aspirate revealed few neutrophils but numerous, small, gram-negative coccobacilli. Culture of blood and tracheal aspirate yielded florid growth of nontypeable Haemophilus influenzae.
Full-term infant (note ossified proximal humeral epiphyses, consistent with full term) with progressive respiratory distress from birth following delivery to a febrile mother through thick, particulate, meconium-containing fluid and recovery of copious meconium from the trachea. Right clavicle is fractured without displacement. Note the coarse dense infiltrates obscuring the cardiothymic silhouette bilaterally with superimposed prominent air bronchograms. Listeria monocytogeneswas recovered from the initial blood culture.
Patchy infiltrates most prominent along left cardiothymic margin in a full-term infant (note proximal humeral ossific nuclei) born to an afebrile woman 18 hours after membranes ruptured. The infant was initially vigorous but developed gradual onset of progressive respiratory distress beginning at 2 hours and prompting endotracheal intubation and transfer to a tertiary center at age 10 hours. Note blunting of the right costophrenic angle, a thin radiodense rim along the lateral right hemithorax, and a fluid line in the right major fissure, all consistent with pleural effusion. Gram staining of pleural fluid recovered at thoracentesis indicated occasional gram-negative bacilli. Tracheal aspirate, pleural fluid, and blood all yielded Escherichia coliupon culture. The dense right upper lobe may appear to suggest lobar infiltrate, but upward bowing of the fissure is more suggestive of volume loss, as in atelectasis, than the bulging picture expected with dense pneumonic change. This lobe appeared normal and appropriately inflated on a subsequent film 2 hours later, also suggestive of atelectasis. Umbilical venous catheter and endotracheal tube were positioned properly on the follow-up film.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.